NCT03912376 is a clinical trial of Quest Hyperspectral Imaging System in Basal Blood Flow, sponsored by Memorial Sloan Kettering Cancer Center.

Who is sponsoring NCT03912376?

NCT03912376 is sponsored by Memorial Sloan Kettering Cancer Center.

What drugs are being tested in NCT03912376?

Interventions in NCT03912376: Quest Hyperspectral Imaging System.

What condition does NCT03912376 study?

NCT03912376 studies Basal Blood Flow.

Is NCT03912376 still recruiting?

NCT03912376 is currently completed. Last updated 15 December 2025.

Are results published for NCT03912376?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2025-12-15 · How we verify

NCT03912376

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of a Device Used to Take Pictures of Skin Blood Flow

Completed Results posted Last updated 15 December 2025

What this trial tests

trial testing Quest Hyperspectral Imaging System in Basal Blood Flow in 8 participants. Completed in 23 September 2024.

Timeline

5 April 2019

Primary endpoint
23 September 2024

23 September 2024

Quick facts

Lead sponsor	Memorial Sloan Kettering Cancer Center
Status	Completed
Study type	OBSERVATIONAL
Enrollment	8
Start date	5 April 2019
Primary completion	23 September 2024
Estimated completion	23 September 2024
Sites	1 location across United States

Drugs / interventions tested

Quest Hyperspectral Imaging System

Conditions studied

Basal Blood Flow — all drugs for Basal Blood Flow →

Sponsor

Memorial Sloan Kettering Cancer Center — full company profile →

Who can join

Adults 18 to 45, any sex, with Basal Blood Flow. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Number of Participants Evaluated to Measure Blood Flow and Oxygenation in the Brachial Artery Primary · Up to 6 months

Number of participants evaluated to measure blood flow and oxygenation in the brachial artery

Group	Value	95% CI
Healthy Volunteer	8

Mean Cutaneous Tissue Oxygen Saturation/StO2 Primary · Up to 6 months

Measure changes in blood flow when vessels constrict or dilate by mean measurements Cutaneous Tissue Oxygen Saturation/StO2

Basal Phase

Group	Value	95% CI
Healthy Volunteer	86.6	± 10.0

Maximum occlusion

Group	Value	95% CI
Healthy Volunteer	72.3	± 15.9

Reperfusion

Group	Value	95% CI
Healthy Volunteer	85.5	± 9.9

Sponsor's own description

The purpose of this study is see fi the hyperspectral camera system (HCS) can measure skin blood flow (perfusion and oxygenation) in healthy people.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Memorial Sloan Kettering Cancer Center trials

Trials by the same sponsor.

NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
NCT07507643 — A Study of Methylprednisolone in People Having Liver Surgery · Phase 3 · recruiting
NCT07483307 — A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Breast Cancer · Phase 2 · recruiting
NCT07459673 — HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term · Phase 2 · recruiting
NCT07449195 — A Study Comparing Two Optical Coherence Tomography Devices in People With Ocular Tumors · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03912376 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Memorial Sloan Kettering Cancer Center
Last refreshed: 15 December 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03912376.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing